BRISTOL-MYERS SQUIBB CO (BMY)       72.45  -0.54 (-0.74%)

72.45  -0.54 (-0.74%)

US1101221083 - Common Stock - After market: 72.3 -0.15 (-0.21%)

BRISTOL-MYERS SQUIBB CO72.45

NYSE:BMY (1/27/2023, 7:04:01 PM)-0.54 (-0.74%)

After market: 72.3 -0.15 (-0.21%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 10-25 2022-10-25/amc Earnings (Next) 02-02 2023-02-02
Ins Owners 0.05% Inst Owners 77.31%
Market Cap 154.04B Shares 2.13B
PE 9.28 Fwd PE 9.02
Dividend Yield 3.07% Analysts 74.07
IPO 07-05 1929-07-05

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BMY Daily chart

Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. The company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. The company also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Company Info

BRISTOL-MYERS SQUIBB CO

430 E. 29Th Street, 14 Floor

New York City NEW YORK 10016

P: 12125464000.0

CEO: Giovanni Caforio

Employees: 32200

Website: https://www.bms.com/

BMY News

News Image17 hours ago - The Motley Fool2 Top Dividend Stocks to Buy in 2023 and Hold Forever

These companies are established leaders in their respective fields.

News Image3 days ago - Seeking AlphaBristol Myers wins EU backing to expand label for anemia therapy (NYSE:BMY)

The EU drug regulator said a group of experts backed expanding the marketing nod for anemia therapy Reblozyl which Bristol Myers (MBY) markets with Merck (MRK). Read the full story here.

News Image3 days ago - Bristol Myers SquibbBristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta ThalassemiaNews Image3 days ago - Bristol Myers SquibbBristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque PsoriasisNews Image3 days ago - The Motley Fool3 Healthcare Stocks to Buy and Hold for the Next 10 Years

These companies have the therapies to boost revenue for a decade.

News Image4 days ago - Seeking AlphaBristol Myers says trial for CAR T therapy met main goal in leukemia (NYSE:BMY)

Bristol Myers Squibb (BMY) announced Thursday that a Phase 1/2 trial for CAR T cell therapy Breyanzi met main goal in adults with certain type of leukemia. Read the full story here.

BMY Twits

Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example